_2020091018165303jzv.jpg "Decoding The World Of ETF")
My Account
The European Medicines Agency (EMA) on December 1 said it would hold an extraordinary meeting on December 29 "at the latest" to consider emergency approval for a Covid-19 vaccine developed by Germany's BioNTech and US giant Pfizer.
"If the data submitted are robust enough to conclude on the quality, safety and effectiveness of the vaccine, EMA... will conclude its assessment during an extraordinary meeting scheduled for 29 December at the latest," the EU regulator said in a statement.
Pfizer and BioNTech earlier announced they had formally applied for conditional EU approval for their jab, following a similar request in the United States.
Big Story | Kunal Shah’s Cred another unicorn in the making? Watch more 
Business Insight | Tata’s proposal to buy Coffee Day Group’s beverage vending business hits roadblock Watch more 
India's manufacturing PMI slips to 3-month low in November Watch more 
Ideas For Profit | Should investors bet on railway engineering stocks? Watch more 
